NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
TORONTO, ONTARIO / ACCESSWIRE / September 3, 2019 / MPX International Corporation (“MPX International”, “MPXI” or the “Company”) (CSE:MPXI; OTC PINK:MPXOF) today announced that its wholly-owned subsidiary, Canveda Inc. (“Canveda”) has achieved Gold Status in its bQb-cert Good Manufacturing Practice (“GMP”) and Quality System Compliance Audit at its 12,000 square foot facility located in Peterborough, Ontario, where it produces high quality cannabis flower. Achieving GMP certification demonstrates MPXI’s commitment to quality and safety in cannabis manufacturing and is an important milestone in the Company’s international growth strategy.
MPXI is strategically positioned to pursue opportunities in the emerging global cannabis marketplace and plans to use its cannabis assets in Canada as a base to export to targeted international markets. Securing bQb-cert GMP certification at its Ontario production facility ensures that MPXI’s products are consistently produced and controlled according to Canada’s highest regulatory standards, enabling the Company to start exporting its products to Australia and other markets. The Company is also working toward EU GMP certification, to facilitate the export of its products to the European Union.
“With a score of 97.7%, achieving this certification proves we have best in class production standards, software and record keeping. As the international markets continue their march towards legalization of cannabis, GMP certification in Canada is more important than ever as it will allow us to immediately use our Canveda facility as a portal to export our products internationally,” said W. Scott Boyes, Chairman, President and Chief Executive Officer of MPXI. “As part of our international strategy, we are also working toward authorization to export to the European Union, which has the strictest cannabis GMP standards in the world, while also developing our international assets in Switzerland, Malta and elsewhere. Furthermore, on a national scale, GMP status also provides our Canadian medical cannabis patients with strong quality control assurance, further setting Canveda and its products apart.”
Canveda continues to develop different strain varieties and recently received its final sales licence enabling it to sell fresh and dried cannabis directly to medical patients, provincial and territorial cannabis boards and other licensees holding a licence to sell for medical purposes.
About MPX International Corporation
MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, MPX International’s objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX International’s public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although MPX International believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX International disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
For further information, please contact:
SOURCE: MPX International Corporation